✦ LIBER ✦

734 Peginterferon alpha-2a (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks in patients with HCV genotype 2 OR 3. Final results of the accelerate trial

✍ Scribed by M.L. Shiffman; S. Pappas; L. Nyberg; S. Greenbloom; A. Gibas; B. Bacons; J. Rasenack; F. Suter; M. Diago; A. Lin; A. Soman; S. Zeuzem

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

O.160 16 or 24 weeks of peginterferon al

✍ S. Zeuzem; S. Pappas; L. Nyberg; S. Greenbloom; A. Gibas; B. Bacon; E. Godofsky; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 143 KB

8 24 Week treatment regimen with peginte

✍ P. Ferenci; U. Bergholz; H. Laferl; T.M. Scherzer; A. Maieron; M. Gschwantler; H 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 159 KB

82 Further reduction of ribavirin dose i

✍ P. Ferenci; H. Brunner; H. Laferl; U. Bergholz; M. Rosenbeiger; R. Stauber; A. M 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 122 KB

O.161 High SVR rates with 24 weeks of pe

✍ P. Ferenci; T. Scherzer; H. Laferl; K. Staufer; A. Maieron; M. Gschwantler; H. B 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 140 KB

[606] COMPARISON OF PEGINTERFERON a-2a A

✍ M. Lagging; C. Pedersen; M. Rauning Buhl; M. Farkkila; N. Langeland; K. Morch; G 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 144 KB

Hepatic steatosis in patients with chron

✍ Maribel Rodriguez-Torres; Sugantha Govindarajan; Moises Diago; Thomas Morgan; Bh 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 194 KB